WILMINGTON, N.C.--(BUSINESS WIRE)--PPD, Inc. (Nasdaq: PPDI) today confirmed that Takeda Pharmaceutical Company Limited has notified the European Medicines Agency, or EMEA, that it will postpone its marketing authorization applications (MAA) for alogliptin (SYR-322) and alogliptin/ACTOS (SYR-322-4833), originally planned for mid-2009, because it is initiating a long-term clinical trial for alogliptin.
